Characteristics of Scientific Success in Phase 1 Pediatric Oncology Clinical Trials: Establishing a Need for Integrated Patient-Reported Outcomes Even in Early Phase Trials
Open Access
- 19 April 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Cancer Care Research Online
- Vol. 3 (2) , e039
Abstract
Background: Pediatric clinical trials are particularly vulnerable to challenges in participant accrual, making them more likely to encounter early termination. Objective: To describe clinical trial characteristics of phase 1 pediatric oncology clinical trials registered in ClinicalTrials.gov through 2017. Method: We identified a retrospective cohort and abstracted key clinical trial characteristics from this data source. We calculated a bivariate logistic regression to explore factors related to early trial termination. Results: Over 1400 phase 1 trials were included in this analysis. Only 3.2% of trials included any type of patient-reported outcome (PRO) as a secondary outcome and 21.6% of phase 1 trials did not meet scientific success due to early termination. National Institutes of Health (NIH)-funded phase 1 trials had the lowest percentage of early termination. Conclusions: Phase 1 clinical trials for pediatric patients with cancer are at risk of early termination due to lack of enrollment. A deeper understanding of clinical trial design elements, characteristics, and eligibility determination may contribute to a higher proportion of trials meeting successful enrollment. Implications for Practice: Oncology nurses and nurse scientists uniquely contribute to an understanding of family-centered approaches and should take an active role in trial design for pediatric cancers that could help capture meaningful PROs during a vulnerable clinical trajectory. What Is Foundational: Very little attention has been given to understanding characteristics of phase 1 clinical trials for pediatric cancers that may impact the state of the science and care delivery for patients with advanced pediatric cancer diagnoses.Keywords
This publication has 29 references indexed in Scilit:
- Strategies to Maximize Data Collection Response Rates in a Randomized Control Trial Focused on Children with Medical ComplexityTelemedicine and e-Health, 2016
- Examining Differences in Opportunity and Eligibility for Cancer Clinical Trial Participation Based on Sociodemographic and Disease CharacteristicsOncology Nursing Forum, 2016
- Compliance with Results Reporting at ClinicalTrials.govNew England Journal of Medicine, 2015
- Communication about the risks and benefits of phase I pediatric oncology trialsContemporary Clinical Trials, 2015
- Does phase 1 trial enrollment preclude quality end‐of‐life care? Phase 1 trial enrollment and end‐of‐life care characteristics in children with cancerCancer, 2014
- Characteristics of Clinical Trials Registered in ClinicalTrials.gov, 2007-2010JAMA, 2012
- Achieving Sufficient Accrual to Address the Primary Endpoint in Phase III Clinical Trials from U.S. Cooperative Oncology GroupsClinical Cancer Research, 2012
- Stakeholder perspectives on implementing the National Cancer Institute’s patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)Translational Behavioral Medicine, 2011
- Globalization of Pediatric Research: Analysis of Clinical Trials Completed for Pediatric ExclusivityPediatrics, 2010
- Issues and Challenges With Integrating Patient-Reported Outcomes in Clinical Trials Supported by the National Cancer Institute–Sponsored Clinical Trials NetworksJournal of Clinical Oncology, 2007